142 related articles for article (PubMed ID: 29408042)
1. H6, a novel hederagenin derivative, reverses multidrug resistance in vitro and in vivo.
Yang Y; Guan D; Lei L; Lu J; Liu JQ; Yang G; Yan C; Zhai R; Tian J; Bi Y; Fu F; Wang H
Toxicol Appl Pharmacol; 2018 Feb; 341():98-105. PubMed ID: 29408042
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of novel H6 analogues as drug resistance reversal agents.
Wang X; Ren QW; Liu XX; Yang YT; Wang BH; Zhai R; Qi JG; Tian JW; Wang HB; Bi Y
Eur J Med Chem; 2019 Jan; 161():364-377. PubMed ID: 30384042
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological evaluation of hederagenin derivatives with improved aqueous solubility and tumor resistance reversal activity.
Wang B; Liu S; Huang W; Ma M; Chen X; Zeng W; Liang K; Wang H; Bi Y; Li X
Eur J Med Chem; 2021 Feb; 211():113107. PubMed ID: 33360797
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and tumor drug resistance reversal activity of novel hederagenin derivatives modified by nitrogen-containing heterocycles.
Huang W; Wang Y; Xu S; Qiao H; Cheng H; Wang L; Liu S; Tian Q; Wang R; Wang H; Bi Y
Eur J Med Chem; 2022 Mar; 232():114207. PubMed ID: 35219948
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576.
Mistry P; Stewart AJ; Dangerfield W; Okiji S; Liddle C; Bootle D; Plumb JA; Templeton D; Charlton P
Cancer Res; 2001 Jan; 61(2):749-58. PubMed ID: 11212278
[TBL] [Abstract][Full Text] [Related]
6. Cabozantinib reverses multidrug resistance of human hepatoma HepG2/adr cells by modulating the function of P-glycoprotein.
Xiang QF; Zhang DM; Wang JN; Zhang HW; Zheng ZY; Yu DC; Li YJ; Xu J; Chen YJ; Shang CZ
Liver Int; 2015 Mar; 35(3):1010-23. PubMed ID: 24621440
[TBL] [Abstract][Full Text] [Related]
7. Reversal of P-glycoprotein-mediated multidrug resistance is induced by saikosaponin D in breast cancer MCF-7/adriamycin cells.
Li C; Guan X; Xue H; Wang P; Wang M; Gai X
Pathol Res Pract; 2017 Jul; 213(7):848-853. PubMed ID: 28554760
[TBL] [Abstract][Full Text] [Related]
8. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
Chen LM; Liang YJ; Ruan JW; Ding Y; Wang XW; Shi Z; Gu LQ; Yang XP; Fu LW
J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852
[TBL] [Abstract][Full Text] [Related]
9. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
[TBL] [Abstract][Full Text] [Related]
10. Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrine.
Jin J; Wang FP; Wei H; Liu G
Cancer Chemother Pharmacol; 2005 Feb; 55(2):179-88. PubMed ID: 15378274
[TBL] [Abstract][Full Text] [Related]
11. Systematic evaluation of multifunctional paclitaxel-loaded polymeric mixed micelles as a potential anticancer remedy to overcome multidrug resistance.
Zhang J; Zhao X; Chen Q; Yin X; Xin X; Li K; Qiao M; Hu H; Chen D; Zhao X
Acta Biomater; 2017 Mar; 50():381-395. PubMed ID: 27956367
[TBL] [Abstract][Full Text] [Related]
12. Immuno-oncology agent IPI-549 is a modulator of P-glycoprotein (P-gp, MDR1, ABCB1)-mediated multidrug resistance (MDR) in cancer: In vitro and in vivo.
De Vera AA; Gupta P; Lei Z; Liao D; Narayanan S; Teng Q; Reznik SE; Chen ZS
Cancer Lett; 2019 Feb; 442():91-103. PubMed ID: 30391357
[TBL] [Abstract][Full Text] [Related]
13. Reversal of P-gp-mediated multidrug resistance by Bromotetrandrine in vivo is associated with enhanced accumulation of chemotherapeutical drug in tumor tissue.
Chen LM; Liang YJ; Zhang X; Su XD; Dai CL; Wang FP; Yan YY; Tao LY; Fu LW
Anticancer Res; 2009 Nov; 29(11):4597-604. PubMed ID: 20032409
[TBL] [Abstract][Full Text] [Related]
14. Substituted tetrahydroisoquinoline compound B3 inhibited P-glycoprotein-mediated multidrug resistance in-vitro and in-vivo.
Fang W; Li Y; Cai Y; Kang K; Yan F; Liu G; Huang W
J Pharm Pharmacol; 2007 Dec; 59(12):1649-55. PubMed ID: 18053326
[TBL] [Abstract][Full Text] [Related]
15. Reversal of P-gp and MRP1-mediated multidrug resistance by H6, a gypenoside aglycon from Gynostemma pentaphyllum, in vincristine-resistant human oral cancer (KB/VCR) cells.
Zhu H; Liu Z; Tang L; Liu J; Zhou M; Xie F; Wang Z; Wang Y; Shen S; Hu L; Yu L
Eur J Pharmacol; 2012 Dec; 696(1-3):43-53. PubMed ID: 23051672
[TBL] [Abstract][Full Text] [Related]
16. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.
Koo JS; Choi WC; Rhee YH; Lee HJ; Lee EO; Ahn KS; Bae HS; Ahn KS; Kang JM; Choi SU; Kim MO; Lu J; Kim SH
Life Sci; 2008 Nov; 83(21-22):700-8. PubMed ID: 18845169
[TBL] [Abstract][Full Text] [Related]
17. Co-encapsulation of paclitaxel and baicalein in nanoemulsions to overcome multidrug resistance via oxidative stress augmentation and P-glycoprotein inhibition.
Meng L; Xia X; Yang Y; Ye J; Dong W; Ma P; Jin Y; Liu Y
Int J Pharm; 2016 Nov; 513(1-2):8-16. PubMed ID: 27596118
[TBL] [Abstract][Full Text] [Related]
18. Reversal of multidrug resistance by co-delivery of paclitaxel and lonidamine using a TPGS and hyaluronic acid dual-functionalized liposome for cancer treatment.
Assanhou AG; Li W; Zhang L; Xue L; Kong L; Sun H; Mo R; Zhang C
Biomaterials; 2015 Dec; 73():284-95. PubMed ID: 26426537
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and discovery of ocotillol-type amide derivatives as orally available modulators of P-glycoprotein-mediated multidrug resistance.
Ren Q; Yang G; Guo M; Guo J; Li Y; Lu J; Yang Q; Tang H; Li Y; Fang X; Sun Y; Qi JG; Tian J; Wang H
Eur J Med Chem; 2019 Jan; 161():118-130. PubMed ID: 30347326
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo characterizations of tetrandrine on the reversal of P-glycoprotein-mediated drug resistance to paclitaxel.
Zhu X; Sui M; Fan W
Anticancer Res; 2005; 25(3B):1953-62. PubMed ID: 16158930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
